Literature DB >> 22943034

Prazosin for the treatment of nightmares related to posttraumatic stress disorder: a review of the literature.

Steven M Hudson1, Travis E Whiteside, Raymond A Lorenz, Kurt A Wargo.   

Abstract

BACKGROUND: Posttraumatic stress disorder (PTSD) is a psychiatric disorder with symptoms that include insomnia due to hyperarousal and recurring nightmares. These symptoms are believed to be due to a conditioned response that is regulated by norepinephrine. Prazosin, an α(1) antagonist, can decrease levels of norepinephrine in the central nervous system, thereby reducing nightmares related to PTSD. DATA SOURCES: A literature search was conducted for all studies evaluating the effectiveness of prazosin as therapy for nightmare symptoms of PTSD. MEDLINE was utilized to identify all English-language studies published between 1966 and March 2011. Keywords searched included prazosin, PTSD, and nightmares.
RESULTS: Eleven studies were identified, including 4 open-label trials, 4 retrospective chart reviews, and 3 placebo-controlled trials. Prazosin demonstrated favorable clinical efficacy and was found to be safe for relieving PTSD-associated nightmares.
CONCLUSIONS: Current data indicate that prazosin is an effective agent for the treatment of nightmares associated with PTSD. However, the data are limited by small study sizes, lack of diversified investigators, and lack of regional diversity.

Entities:  

Year:  2012        PMID: 22943034      PMCID: PMC3425466          DOI: 10.4088/PCC.11r01222

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  25 in total

1.  The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases.

Authors:  M A Raskind; D J Dobie; E D Kanter; E C Petrie; C E Thompson; E R Peskind
Journal:  J Clin Psychiatry       Date:  2000-02       Impact factor: 4.384

2.  Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan.

Authors:  Charles W Hoge; Jennifer L Auchterlonie; Charles S Milliken
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

3.  Bizarre behavior in a patient treated with prazosin for PTSD.

Authors:  Claudia L Reardon; Robert M Factor
Journal:  Am J Psychiatry       Date:  2008-06       Impact factor: 18.112

4.  The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder.

Authors:  Fletcher Taylor; Murray A Raskind
Journal:  J Clin Psychopharmacol       Date:  2002-02       Impact factor: 3.153

Review 5.  Clinician-administered PTSD scale: a review of the first ten years of research.

Authors:  F W Weathers; T M Keane; J R Davidson
Journal:  Depress Anxiety       Date:  2001       Impact factor: 6.505

Review 6.  Prazosin for the treatment of posttraumatic stress disorder sleep disturbances.

Authors:  Lisa J Miller
Journal:  Pharmacotherapy       Date:  2008-05       Impact factor: 4.705

7.  Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study.

Authors:  Murray A Raskind; Elaine R Peskind; Evan D Kanter; Eric C Petrie; Allen Radant; Charles E Thompson; Dorcas J Dobie; David Hoff; Rebekah J Rein; Kristy Straits-Tröster; Ronald G Thomas; Miles M McFall
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

8.  The effect of propranolol on posttraumatic stress disorder in burned service members.

Authors:  Laura L McGhee; Christopher V Maani; Thomas H Garza; Peter A Desocio; Kathryn M Gaylord; Ian H Black
Journal:  J Burn Care Res       Date:  2009 Jan-Feb       Impact factor: 1.845

9.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12
View more
  8 in total

Review 1.  Treatment of Post-Traumatic Stress Disorders with the Alpha-1 Adrenergic Antagonist Prazosin.

Authors:  Philippe Yves Rémy Simon; Pierre-François Rousseau
Journal:  Can J Psychiatry       Date:  2016-07-19       Impact factor: 4.356

Review 2.  Sleep-dependent memory consolidation and its implications for psychiatry.

Authors:  Monique Goerke; Notger G Müller; Stefan Cohrs
Journal:  J Neural Transm (Vienna)       Date:  2015-10-30       Impact factor: 3.575

Review 3.  Sleep and Dreaming in Posttraumatic Stress Disorder.

Authors:  Katherine E Miller; Janeese A Brownlow; Steve Woodward; Philip R Gehrman
Journal:  Curr Psychiatry Rep       Date:  2017-08-22       Impact factor: 5.285

Review 4.  Adverse Childhood Events, Post-Traumatic Stress Disorder, Infectious Encephalopathies and Immune-Mediated Disease.

Authors:  Robert C Bransfield
Journal:  Healthcare (Basel)       Date:  2022-06-17

Review 5.  Therapeutic Symptomatic Strategies in the Parasomnias.

Authors:  Raffaele Manni; Gianpaolo Toscano; Michele Terzaghi
Journal:  Curr Treat Options Neurol       Date:  2018-06-05       Impact factor: 3.598

Review 6.  The link between suicide and insomnia: theoretical mechanisms.

Authors:  W Vaughn McCall; Carmen G Black
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

Review 7.  Patient-reported outcomes in post-traumatic stress disorder. Part II: focus on pharmacological treatment.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

8.  Doxazosin for the treatment of nightmare disorder: A diary-based case study.

Authors:  Ståle Pallesen; Hilde Sofie Hamre; Nina Lang; Bjørn Bjorvatn
Journal:  SAGE Open Med Case Rep       Date:  2020-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.